Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

A recent analysis from the MPACT trial supported the use of carbohydrate antigen 19-9 (CA19-9) decrease as a predictive marker for survival in patients receiving nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer; however, CA19-9 cannot be used in this capacity for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H., Von Hoff, D. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959922/
https://www.ncbi.nlm.nih.gov/pubmed/27240995
http://dx.doi.org/10.1093/annonc/mdw177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959922/
https://www.ncbi.nlm.nih.gov/pubmed/27240995
http://dx.doi.org/10.1093/annonc/mdw177

Ejemplares similares